

# **ADMET 2015**

Wednesday 13 May 2015 SCI, London, UK



Organised by SCI's Young Chemists' Panel

# **ADMET 2015**

Wednesday 13 May 2015, SCI, London, UK

## **Synopsis**

The aim of the day is to provide participants with a practical understanding of ADMET parameters, how to diagnose common ADMET problems and how to improve compound design to overcome these problems.

### Attendees

The event is aimed at organic chemists (graduate or PhD) working within a pharmaceutical research environment and students thinking about a career in this sector. Participants are provided with a booklet containing the material presented, worked examples and literature references.

# Registration

**Standard rates from Monday 13 April:** SCI Members £140, Non-Members £205, SCI Student Member £50, SCI Subsidised Members £100\* (\*criteria applies)

# Exhibition

For information on exhibition and sponsorship opportunities, please email jacqui.colgate@soci.org.

## With thanks to our sponsor



# For further details:

SCI Conference Department 14/15 Belgrave Square, London, SW1X 8PS T: +44 (0) 20 7598 1561 E: conferences@soci.org W: www.soci.org/events

### Programme

#### Absorption

- Practical understanding of concepts and parameters
- How do you know you have a problem?
- Sources of problem Solubility, Permeability, PGP Efflux
- · Chemical strategies to improve absorption
- Worked examples

#### Metabolism and clearance I

- Practical understanding of concepts and parameters
- · How do you know you have a problem?
- Sources of problem Phase I / Phase II Metabolism
- · Chemical strategies to address metabolism
- Worked examples

### Metabolism and clearance II

- Cytochrome P450s and Drug-Drug interactions
- Volume of distribution how to understand and influence
- Plasma protein binding impact and influence
- Worked examples

### Drug toxicity and toxicology

- Context and common issues
- Design strategies to mitigate risks of hERG, phospholipidosis, reactive metabolites and genotoxicity

# **Speakers**

Ted Parton, UCB Peter Astles, Eli Lilly Darren McKerrecher, Astrazeneca

